Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
- HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.
- 10/04/2022
|
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
- 09/01/2022
|
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
- HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update.
- 08/11/2022
|
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
- - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -
- 03/24/2022
|
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
- HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT.
- 01/26/2022
|
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
- HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million for continued listing of the company's common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the company's recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.
- 12/13/2021
|
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
- - Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology -
- 11/04/2021
|
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
- HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
- 09/03/2021
|
BLCM Stock: Over 12% Increase Pre-Market Explanation
- The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.
- 09/01/2021
|
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
- HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum's CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.
- 09/01/2021
|
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grant with an effective date of July 26, 2021. The stock options were granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/26/2021
|
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
- HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company's CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid. CaspaCIDe may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs.
- 06/28/2021
|
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
- HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.
- 05/17/2021
|
Bellicum Pharmaceuticals: Narrowing The Thesis And Simplifying The Investment
- Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bellicum was only a few quarters away from being a commercial company and collecting revenue. Now, the company is back to proof-of-concept and Phase I trials.
- 05/13/2021
|
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript
- Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript
- 03/30/2021
|
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
- Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2
- 03/30/2021
|
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
- Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT
- 03/23/2021
|
BLCM Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) has increased by over 15% pre-market. This is why it happened.
- 03/04/2021
|
BLCM Stock Price Increases Over 40% Pre-Market: Why It Happened
- The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is trading at over 40% pre-market. This is why it happened.
- 01/29/2021
|
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
- HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.
- 01/28/2021
|
Bet on Rising P/E With These 5 Top-Ranked Stocks
- Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- 01/06/2021
|
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why
- Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/25/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- 12/18/2020
|
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
- HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum's first dual switch GoCAR-T® product candidate that incorporates the company's iMC activation and CaspaCIDe® safety switch technologies.
- 12/10/2020
|
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
- HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.
- 12/07/2020
|
Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy?
- Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)? The smart money sentiment can provide an answer to this question.
- 11/27/2020
|
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
- Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year
- 11/05/2020
|
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
- HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.025 and each pre-funded warrant to purchase one share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.024. The exercise price of each pre-funded warrant is $0.001 per share and the exercise price of each accompanying warrant to purchase common stock is $6.50 per share.
- 11/03/2020
|
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
- HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum's existing healthcare-dedicated institutional investors.
- 10/29/2020
|
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
- HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.
- 10/29/2020
|
Bellicum Pharmaceuticals (BLCM) Investor Presentation - Slideshow
|
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
- Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020Management to host conference call and webcast today at 5 p.m. ET / 2 p.m. PTHOUSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2020 and provided an operational update.“Bellicum continued to make significant progress in the second quarter, highlighted by FDA clearance of our IND for BPX-603, our first dual-switch Go-CAR-T® product candidate to enter clinical development,” said Rick Fair, President and Chief Executive Officer of Bellicum. “We expect to be entering a period of accelerated news flow for our company with multiple data readouts planned in the next 24 months, starting in the fourth quarter with our initial presentation of the BPX-601 Phase 1 cohort 5C with repeat rimiducid.”Program Highlights and Current UpdatesBPX-601 GoCAR-T® * Bellicum continues to enroll patients in cohort 5C of the BPX-601 clinical trial in second-line metastatic pancreatic cancer to evaluate the safety of repeat rimiducid dosing to re-activate BPX-601 cells over time. Bellicum plans to present interim results for this cohort at a medical meeting by the end of the year. The study has experienced modest enrollment delays and data collection issues related to the COVID-19 pandemic which may impact the number of patients, duration of follow-up and data to be presented. * In addition, Bellicum has submitted an amendment to the FDA to modify the BPX-601 trial by: (1) expanding eligibility to third-line pancreatic cancer patients; (2) extending dose escalation of BPX-601 cells to 1x107 cells/kg; and (3) opening a cohort in relapsed metastatic castration-resistant prostate cancer. The company expects to begin enrolling under this amended protocol later this year.BPX-603 GoCAR-T * In June 2020, Bellicum received clearance from the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for BPX-603. BPX-603 is a GoCAR-T product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates both the company’s iMC activation and CaspaCIDe® safety switch technologies and the company plans to initiate a Phase 1/2 basket trial in solid tumors that express HER2 later this year.BCMA GoCAR-NK™ Program * In May 2020, preclinical data from Bellicum’s GoCAR-NK cell program was published in the digital edition of Blood Advances, a journal published by The American Society of Hematology, illustrating that the incorporation of iMC into CAR-NK cells was found to improve cell proliferation and persistence, stimulate cytokine production, and enhance innate cytotoxicity against tumor cells in multiple models. Preclinical development activities are continuing for Bellicum’s GoCAR-NK program targeting B-cell maturation antigen, or BCMA, for the treatment of multiple myeloma. Management expects to present additional preclinical data for this program by the end of 2020.Corporate Highlights * In April 2020, Bellicum closed a transaction in which The University of Texas MD Anderson Cancer Center acquired Bellicum’s approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space, for $15.0 million. Concurrent with this transaction, Bellicum partially repaid approximately $7.0 million of its Oxford Finance debt obligations.Second Quarter 2020 Financial ResultsR&D Expenses: Research and development (R&D) expenses were $11.8 million and $22.2 million for the three and six months ended June 30, 2020, respectively, compared to $20.0 million and $36.9 million for the three and six months ended June 30, 2019, respectively. The reduction in expenses in the second quarter and first half of 2020 resulted primarily from reduced expenses related to reduced rivo-cel related activities, reduced expenses resulting from the manufacturing facility sale and the reduction in force implemented during the second half of 2019, partially offset by an increase in expenses related to the GoCAR™ programs.G&A Expenses: General and administrative (G&A) expenses were $3.8 million and $7.9 million for the three and six months ended June 30, 2020, respectively, compared to $7.5 million and $15.1 million for the three and six months ended June 30, 2019, respectively. The reduction in expenses during the second quarter and first half of 2020 relative to the comparable period in 2019 was primarily due to the reduction in rivo-cel related commercialization activities as well as the effects of the reduction in force that reduced employee-related charges.Loss from Operations: Bellicum reported a loss from operations of $11.8 million and $26.4 million for the three and six months ended June 30, 2020, respectively, compared to a loss from operations of $26.2 million and $50.0 million for the three and six months ended June 30, 2019, respectively. The results for the three and six months ended June 30, 2020 included a net gain on dispositions of $3.8 million due to the manufacturing facility sale. Cash used in operating activities was $30.5 million for the six months ended June 30, 2020, compared to cash used in operating activities of $46.0 million for the six months ended June 30, 2019.Net Loss: Bellicum reported net loss of $43.2 million and $25.6 million for the three and six months ended June 30, 2020, respectively, compared to a net loss of $26.9 million and $51.5 million for the three and six months ended June 30, 2019, respectively. The results included a non-cash loss of $30.7 million and non-cash gain of $2.1 million related to the change in fair value of warrant and private placement option liability for the three and six months ended June 30, 2020, respectively.Shares Outstanding: As of June 30, 2020, Bellicum had 5,059,779 shares of common stock and 534,000 shares of preferred stock outstanding. Each share of preferred stock can be converted into 10 shares of common stock.Cash Position and Guidance: Bellicum reported cash and cash equivalents and restricted cash totaling $68.0 million as of June 30, 2020, compared to $93.8 million as of December 31, 2019. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements into the second half of 2021. Management expects cash utilization of $55 to $65 million in 2020.Potential MilestonesBelow is a summary of notable anticipated milestones for our ongoing programs: BPX-601 * * Initial Phase 1 cohort 5C data (repeat rimiducid) – pancreatic cancer: Q4’20 * Phase 1/2 data update – pancreatic cancer: 2H’21 * Initial Phase 1/2 data – prostate cancer: 2022 BPX-603 * * Initiate Phase 1/2 trial: 2H’20 * Initial Phase 1 data: 2H’21 * Phase 1 data update: 2022 BCMA GoCAR-NK * * Preclinical data update: Q4’20 * Preclinical data update: 2H’21 * IND clearance: 2022Conference Call and WebcastBellicum’s management will host a webcast and conference call today at 5 p.m. ET / 2 p.m. PT, August 6, 2020, to discuss the financial results for the second quarter 2020 and provide a corporate update. The live call may be accessed by dialing (800) 920-0677 for domestic callers and (212) 231-2908 for international callers. A live webcast of the call will be available from the Investors and Media section of the company’s website at www.bellicum.com and a replay will be available shortly after the live event.About Bellicum PharmaceuticalsBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities and expectations regarding presenting data for our BPX-601, BPX-603, GoCAR-NK and other cell therapy programs, our ability to enroll patients and generate meaningful clinical data in our ongoing GoCAR clinical programs; whether we will be able to amend the ongoing BPX-601 protocol to treat additional patient populations including patients with prostate cancer; our ability to initiate a clinical trial in BPX-603, including site selection and start-up; our ability to make additional progress on the nonclinical development of the BCMA-GoCAR-NK candidate; the potential impact of the COVID-19 on enrollment in clinical trials and other aspects of our business; our expected cash runway; and the anticipated milestones identified above.
- 08/06/2020
|
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of July 31, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $6.71 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2019 Equity Incentive Plan and a stock option agreement covering the grant.About Bellicum PharmaceuticalsBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com. Source: Bellicum PharmaceuticalsInvestors: Robert H. Uhl Managing Director Westwicke ICR 858-356-5932 Robert.uhl@westwicke.com
- 07/31/2020
|
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
- Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PTHOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the second quarter 2020 after the close of U.S. markets on Thursday, August 6, 2020. Management will host a webcast and conference call at 5 p.m. ET / 2 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 800-920-0677 (U.S. domestic) and 212-231-2908 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website following the call.About Bellicum PharmaceuticalsBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.Source: Bellicum PharmaceuticalsInvestors: Robert H. Uhl Managing Director Westwicke ICR 858-356-5932 Robert.uhl@westwicke.com
- 07/30/2020
|
Tower Research Capital LLC TRC Acquires 4,745 Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
- Tower Research Capital LLC TRC boosted its holdings in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 58.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,917 shares of the biopharmaceutical company’s stock after purchasing an additional 4,745 shares during the quarter. Tower Research Capital […]
- 07/02/2020
|
Home owners 'threatened' with knife by teenager demanding money
- Two teenagers - including a 15-year-old boy - have been arrested
- 06/27/2020
|
Xconomy: Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies
- Creating cell therapies for cancer is a complex process. The business case for them has proven tricky, too. Biotech veterans Tom Farrell and Peter Flynn
- 06/26/2020
|
4 Buckhead Business Organizations Are Coming Together
- Livable Buckhead is joining leading Buckhead organizations to advance the local quality of the life and business environment in Buckhead.
- 06/24/2020
|
How police solved murder of ex-army officer in North Lincolnshire
- Lincolnshire Police used groundbreaking methods to secure convictions of two suspects in former Yugoslavia
- 06/21/2020
|
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
|
Masked thugs traumatise teen after robbing him at knife point in Edinburgh
- The 15-year-old was left 'traumatised' after being confronted by two men in the Portobello area on Sunday.
- 06/16/2020
|
Boy, 15, robbed at knifepoint - Evening Telegraph
- A 15-year-old boy has been robbed at knifepoint in Edinburgh.
- 06/16/2020
|
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
- HOUSTON, June 15, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced.
- 06/15/2020
|
Gang attack in Glasgow's Govan leaves one man in hospital
- The 22-year-old victim was rushed to hospital after the attack and police are hunting four teens.
- 06/15/2020
|
Here is What Hedge Funds Think About Bellicum Pharmaceuticals Inc (BLCM)
- In this article you are going to find out whether hedge funds think Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
- 06/12/2020
|
Gang of five men attempt to steal dog from woman
- Detectives are urging anyone who was in the area and saw anything that may help their investigation to come forward
- 06/09/2020
|
Woman fights off gang who tried to steal her dog as she walked it
- Dog thieves snatched woman's wrist and tried to yank the lead from her hand
- 06/09/2020
|
Celyad's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:CYAD)
- Celyad reports positive data for allogenic CAR-T. Sanofi is approved in the EU for Sarclisa in Multiple Myeloma. Abiomed gets IND for its Covid-19 iNKT therapy.
- 06/05/2020
|
Man pleads guilty to grooming offences
- He believed he was talking to a 14-year-old girl, but was actually an adult who reported it to the police
- 06/04/2020
|
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
- NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...
- 06/03/2020
|
Bellicum Pharmaceuticals Says M.D. Anderson To Resume, On Phased Basis, Selected Research, Manufacturing Activities
|
Top Ranked Momentum Stocks to Buy for June 1st
- Top Ranked Momentum Stocks to Buy for June 1st
- 06/01/2020
|
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- The Compensation Committee of the Board of Directors approved the grants with an effective date of May 29, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $7.63 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
- 05/29/2020
|
Bellicum Announces The Publication Of Its Preclinical Data From Its GoCAR-NK Cell Program
|
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
- HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the.
- 05/27/2020
|
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
- HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that.
- 05/27/2020
|
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
|
All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy
- Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 05/22/2020
|
96 Biggest Movers From Friday
|
Bellicum Pharmaceuticals Q1 EPS $1.090 May Not Compare To $(0.550) YoY
|
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
- Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.
- 05/07/2020
|
The Bellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Is Down 98% So Some Shareholders Are Very Salty
- Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
- 05/06/2020
|
52 Biggest Movers From Yesterday
|
44 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
The Peck Company Holdings, Inc. (NASDAQ: PECK) shares climbed 68.5% to $4.50.
Core Molding Technologies, Inc. (NYSE: CMT) gained 35.1% to $3.2429.
TriState Capital...
- 04/21/2020
|
Houston pharma co. completes $15M facility sale to M.D. Anderson as drug research stalls
- M.D. Anderson has halted research and development activity on the Houston pharmaceutical firm's product candidates in response to the COVID-19 pandemic.
- 04/17/2020
|
Bellicum Pharma 8-K Shows MD Anderson Informed Co. Of Decision To Temporarily Halt Research Activity Given Exceptional Circumstances Related To Coronavirus Pandemic
|
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Short Interest Update
- Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 417,700 shares, a decline of 29.1% from the March 15th total of 589,100 shares. Based on an average trading volume of 161,100 shares, the days-to-cover ratio is […]
- 04/16/2020
|
Bellicum Completes Sale of Houston Facility
- Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson.
- 04/15/2020
|
Bellicum Completes Sale of Houston Facility
|
86 Biggest Movers From Yesterday
|
Edited Transcript of BLCM earnings conference call or presentation 12-Mar-20 9:00pm GMT
- Q4 2019 Bellicum Pharmaceuticals Inc Earnings Call
- 03/31/2020
|
Bone Marrow Transplant Rejection Treatment Market Size, Share, 2020 dynamics (drivers, restraints, and opportunities), plans, Competitive Landscape and Growth by Forecast to 2023
- Mar 20, 2020 (The Expresswire) --
Global “Bone Marrow Transplant Rejection Treatment Market” Report 2020 is a comprehensive, professional report provides a...
- 03/20/2020
|
144 Biggest Movers From Friday
- Gainers
Contura Energy, Inc. (NYSE: CTRA) shares surged 64.7% to close at $4.89 on Friday. Contura is expected to release Q4 results on March 18.
Exterran Corporation (NYSE: EXTN...
- 03/16/2020
|
Mid-Afternoon Market Update: Dow Surges Over 800 Points; Amyris Shares Slide
- Toward the end of trading Friday, the Dow traded up 3.84% to 22,013.72 while the NASDAQ rose 3.32% to 7,440.54. The S&P also rose, gaining 3.69% to 2,572.16. South Korea...
- 03/13/2020
|
88 Stocks Moving In Friday's Mid-Day Session
- Gainers
CorePoint Lodging Inc. (NYSE: CPLG) gained 55.6% to $5.29 after the company reported results for its fourth quarter.
OPKO Health, Inc. (NASDAQ: OPK) climbed 44.4% to $2....
- 03/13/2020
|
Mid-Day Market Update: Citi Trends Rises After Q4 Results; Inovio Pharmaceuticals Shares Plunge
- Midway through trading Friday, the Dow traded up 2.26% to 21680.64 while the NASDAQ rose 2.22% to 7,361.97. The S&P also rose, gaining 2.25% to 2,536.54. South Korea confirmed...
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
- Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology.
- 03/12/2020
|
Bellicum Pharmaceuticals, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 ...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Insiders Increased Their Holdings
- We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
- HOUSTON, March 05, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it.
- 03/05/2020
|
Bellicum to Report Fourth Quarter and Full Year —…–9 Financial Results and Provide ...
|
140 Biggest Movers From Friday
|
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 56'5(c)(4)
|
94 Biggest Movers From Yesterday
- Gainers
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) shares gained 78.5% to close at $3.66 after the company announced a license agreement with Zhejiang HaiChang Biotechnology....
- 02/12/2020
|
80 Biggest Movers From Yesterday
- Gainers
Taubman Centers, Inc. (NYSE: TCO) shares jumped 53.2% to close at $53.12 on Monday. Simon Property Group, Inc. (NYSE: SPG) said Monday it plans to purchase an 80%...
- 02/11/2020
|
Weekly Summary Corporate dividends, name changes, new listings
- NEW YORK (AP) — Changes announced in corporate dividends Feb. 3-Fev. 7. INCREASED DIVIDENDS Activision Blizzard .41 from .37 Aflac Inc .28 from .27 Arch Coal Inc Cl A .50 from .45 Avista Corp .405 from .3875 BCE Inc .8325 from .7925 Booz Allen Hamilton Hldg .31 from .27 CME Group Inc Cl A .85 from .75 Camden Property Trust .83 from .80 Capital Southwest .41 from .40 Columbia Sportswear .26 from .24 Corning Inc .22 from .20 Dunkin Brands Group .4025 from .3750 Equinor ASA .27 from .26 Eversource Energy .5675 from .535 Exponent Inc .19 from .16 First Northwest Bancorp .05 from .04 Gaslog Partners LP .561 from .55 Genpact Ltd .0975 from .085 Gilead Sciences Inc .68 from .63 Hartford Financial .325 from .30 Hawkins Inc .2325 from .23 Highwoods Properties .48 from .475 Intercontinental Exchange .30 from .275 Kemper Corp .30 from .28 Lemaitre Vascular .095 from .085 Meredith Corp .595 from .575 Midland States Bancorp .2675 from .2425 Monolithic .50 from .40 Neenah Inc .47 from .45 New York Times Co .06 from .05 NiSource Inc .21 from .20 Old Dominion Freight Line .23 from .17 Otter Tail Corp .37 from .35 Prudential Financial 1.10 from 1.00 SkyWest Inc .14 from .12 Suncor Energy Inc g .465 from .42 WR Grace & Co .30 from .27 Xylem Inc .26 from .24 SPECIAL DIVIDENDS Banco Bradesco Ord Shares ADR .00423 Columbia Banking System .22 Mid Penn Bancorp .05 Reduced Dividends Westwood Holdings Grp .43 from .72 STOCK DIVIDENDS Parke Bancorp 10pc g- Canadian funds OTHER CORPORATE NEWS...
- 02/07/2020
|
Houston biotech firm raises millions; pharma co. enacts reverse stock split
- Two publicly traded, clinical-stage pharmaceutical companies in Houston worked to better their financial runways Feb. 6 — one through a share purchase agreement, the other through a reverse stock split. Houston-based Moleculin Biotech Inc. (Nasdaq: MBRX), a clinical-stage pharmaceutical company targeting highly resistant tumors, announced a registered direct offering with institutional investors in a Feb. 6 news release. The agreement allows for Moleculin's investors to purchase an aggregate of up to 7.5 million shares and warrants to purchase 5.625 million shares of common stock at a combined public offering price of 80 cents per share.
- 02/07/2020
|
Bellicum Announces Reverse Stock Split
- The effective time of the reverse stock split will be 5 p.m. ET on February 5, 2020. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on February 6, 2020. As previously disclosed, at a special meeting of stockholders held on January 15, 2020, the Company’s stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company’s certificate of incorporation to effect a reverse stock split and a corresponding reduction in the authorized shares of the Company’s common stock.
- 02/05/2020
|
Bellicum Announces 1-For-10 Reverse Stock Split
|
Shares of several healthcare companies are trading higher in sympathy with the overall market on a rebound after increased fear of the Wuhan coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.
|
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Bellicum Pharmaceuticals, Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss. The stock option was granted on January 31, 2020 with an exercise price equal to the closing price of the Company’s common stock on such date. One-fourth of the shares subject to the stock option will vest on the one-year anniversary of Mr. Strauss’ start date and the remainder of the shares will vest in a series of 36 successive equal monthly installments thereafter.
- 01/31/2020
|
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 56'5(c)(4)
|
MLCO, LVS among premarket losers
- NeuroMetrix (NASDAQ:NURO) -33% on Q4 results.NIO (NYSE:NIO) -14%.Genprex (NASDAQ:GNPX) -9%.Epizyme (NASDAQ:EPZM) -10%.Bellicum Pharmaceuticals (NASDAQ:BLCM) -12%.Pintec Technology Holdings (NASDAQ:PT)
- 01/27/2020
|
70 Biggest Movers From Friday
- Gainers
NanoViricides Inc (NYSE: NNVC) shares rose 54.5% to close at $8.45 on Friday after gaining 43.2% on Thursday.
SAExploration Holdings Inc (NASDAQ: SAEX) shares jumped 33%...
- 01/27/2020
|
INO, BLDP among premarket gainers
- Camber Energy (NYSEMKT:CEI) +36% on announcing letter of intent regarding Camber’s proposed acquisition of Viking.Tonix Pharmaceuticals Holding (NASDAQ:TNXP) +32% on advancement of TNX-102 SL.eHealth
- 01/24/2020
|
The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: MESO ) Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Soligenix, Inc. (NASDAQ: SNGX ) Syneos Health Inc (NASDAQ: SYNH ) TELA Bio Inc (NASDAQ: TELA ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 23) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Evolus Inc (NASDAQ: EOLS ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Second Sight Medical Products Inc (NASDAQ: EYES ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Therapix Biosciences Ltd – ADR (NASDAQ: TRPX ) Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020 Stocks In Focus Kura Oncology Announces Departure of Chief Medical Officer Kura Oncology said Antonio Gualberto, serving as Head of Development and Chief Medical Officer, will leave to pursue other opportunities.
- 01/24/2020
|
15 Biotechnology Stocks Moving In Thursday's After-Market Session
-
Gainers
• Alector, Inc. (NASDAQ:ALEC) stock rose 10.8% to $25.79 during Thursday's after-market session. The most recent rating by BTIG, on November 21, is at Buy...
- 01/24/2020
|
Bellicum Pharmaceuticals shares are trading lower after the company reported the Phase 1 translational results for its BPX-601 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
|
20 Healthcare Stocks Moving In Thursday's After-Market Session
|
60 Biggest Movers From Friday
|
Bellicum Pharmaceuticals To Sell Houston Facility To University Of Texas MD Anderson Cancer Center For $15M
|
The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings
|
Netflix And Dow Heavyweights Into The Earnings Confessional
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 01/18/2020
|
Mid-Morning Market Update: Markets Open Higher; Schlumberger Tops Q4 Views
- Following the market opening Friday, the Dow traded up 0.17% to 29346.02 while the NASDAQ rose 0.22% to 9,377.27. The S&P also rose, gaining 0.24% to 3,324.93.
Leading and...
- 01/17/2020
|
38 Stocks Moving In Friday's Mid-Day Session
|
Bellicum Pharma Highlights Will Present New Translational Data For BPX-601 At ASCO 2020 Gastrointestinal Cancers Symposium Fri., Jan. 24, 2020
|
Bellicum Pharmaceuticals Licenses Its CaspaCIDe Safety Switch To MD Anderson; Co. To Receive $5M Upfront Payment And Undisclosed Future Milestones
|
X-Square Capital, LLC Buys Popular Inc, PowerShares QQQ Trust Ser –, AVEO Pharmaceuticals ...
|
Bellicum Pharma Offers Preclinical Data For GoCAR-NK Cell Program At SITC
|
23 Healthcare Stocks Moving In Thursday's Pre-Market Session
|
Bellicum Pharmaceuticals Q3 EPS $(0.68) Misses $(0.53) Estimate
|
Bellicum up 26% ahead of data presentation on CAR program
|
Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline
|
The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise
|
Stocks That Hit 52-Week Lows On Wednesday
|
Talented musician drowned in Merlin's Cave following Tintagel fairy ball
- The 23-year-old care worker 'would help anyone'
- 10/03/2019
|
Top Ranked Momentum Stocks to Buy for September 23rd
|
22 Healthcare Stocks Moving In Monday's Pre-Market Session
|
Bellicum: Moving Toward MAA Submission For Rivo-Cel
|
Bellicum Pharmaceuticals (BLCM) Presents At 2019 Wells Fargo Healthcare Conference - Slideshow
|
Bellicum: Strong Trial Data, Poor Share Price, Dire Financials
|
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 56'5(c)(4)
|
Top 10 Movers Via Benzinga Pro's Screener Tool For Mid-Day of Tuesday., August 27, 2019
|
Bellicum Pharmaceuticals 13D Shows Baker Bros. Advisors Holds 5.8% Stake In Co.
|
Bellicum Pharmaceuticals Reports Aggregate Gross Proceeds Of $69.6 Million from $139.6 Million Public Offering
|
22 Healthcare Stocks Moving In Tuesday's Pre-Market Session
|
Bellicum Pharma Prices 575K Share Offering At $1/Unit
|
Bellicum Pharmaceuticals Announces Proposed $5'. ...
|
Stocks That Hit 52-Week Lows Of Monday
|
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering
|
Stocks That Fell Through 52-Week Lows Wednesday
|
The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
|
Bellicum Pharmaceuticals Q2 EPS $(0.58) Misses $(0.54) Estimate, Sales $1.39M Beat $870K Estimate
|
Stocks That Set New 52-Week Lows Friday Morning
|
Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
|
Bellicum: Ready To Transition Into A Commercial-Stage Company
|
The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
|
Bellicum Pharma S-3 Shows Registration For $400M Mixed Securities Offering
|
Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.
|
Worst Value Picks Now: Bellicum Pharmaceuticals, Inc. (BLCM), Lululemon Athletica Inc. (LULU) | Post Analyst
- current P/S is an unimpressive 49.36. The overall Major Pharmaceuticals group has an average P/S ratio of 43.63, which is significantly worse than the sector’s 11.66. traded at an unexpectedly high level on 07/08/2019 when the stock experienced a 2.27% gain to a closing price of $1.8. The company saw 1135670 shares trade hands over …
- 07/09/2019
|
Bellicum Pharmaceuticals Announces Rivo-cel Achieved Primary Endpoint In Pediatric Registrational Trial
|
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
|
66 Biggest Movers From Yesterday
|
CEL-SCI and Bellicum Pharmaceuticals among healthcare gainers; INSYS Therapeutics leads the losers
|
The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
|
ContraVir Pharmaceuticals leads healthcare gainers; ReWalk Robotics and Bellicum Pharmaceuticals among losers
|
Bellicum: Encouraging Data With A Discouraging Share Price
|
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer at #ASCO19; 62% of Patients Achieved Stable Disease
|
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 56'5(c)(4)
|
The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
|
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
|
The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
|
The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut
|
The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails
|
Bellicum Pharmaceuticals beats by $0.03, beats on revenue
|
50 Biggest Movers From Yesterday
|
Bellicum Pharma 8-K Shows Co. Entered Supply Deal With Miltenyi Biotec Whereby Miltenyi Will Supply Co. With Certain Products Related To Development, Manufacture Of Certain Co. Products
|
60 Biggest Movers From Yesterday
|
48 Stocks Moving In Thursday's Mid-Day Session
|
Bellicum Pharmaceuticals, Inc. - Common Stock Q4 EPS $(0.63) Misses $(0.56) Estimate, Sales $312K Miss $1.19M Estimate
|
30 Stocks Moving In Friday's Pre-Market Session
|
FDA finalizes guidance for expedited review of cell and gene therapy applications
|
Bellicum: Oversold In 2018 And Undervalued In 2019
|
Poseida Therapeutics Files For U.S. IPO
|
50 Biggest Movers From Yesterday
|
30 Stocks Moving In Thursday's Mid-Day Session
|
60 Biggest Movers From Friday
|
